Doctors to Look at Dosage Formulations for Sannabis Products

New Colombia Resources Inc. (OTCQB:NEWC) announced that Sannabis SAS, its subsidiary, is putting together a team of doctors that will work towards establishing dosage formulations for Sannabis products.

The company also said that it will soon be making a definitive decision on how to spin off Sannabis.

As quoted in the press release:

The group will focus on epilepsy, fibromyalgia, and chronic pain. Patients currently purchase Sannabis products for these and other ailments. Sannabis supplies many kids with epilepsy and autism that have shown significant improvement. “After seeing our first pediatric epilepsy patient first hand and hearing from her mother the improvement she has made, makes me more determined than ever to develop an affordable formulation that can be distributed throughout the world,” stated John Campo, President of New Colombia Resources, Inc.

Sannabis and its patients have documented many cases. Sannabis supplies foundations that distribute their products to needy adults and children. They are developing to raise money worldwide to supply needy patients in Colombia.

New Colombia Resources is organizing a U.S. group with an industry veteran to research cannabis pharmaceuticals in Colombia for approval in the U.S. and Colombia. The Company aims for Colombia to become an incubator of cannabis medicines for researchers around the world.

Click here to read the full New Colombia Resources Inc. (OTCQB:NEWC) press release. marketwired